Skip main navigation

Home > Search Results

Main contents starts here

Search Results

81 - 100 of about 405

Total 405 documents found.

  •  
  • CSR in Takeda
  • Throughout our more than 220-year history, Takeda has maintained a strong commitment to society, demonstrating high ethical standards and living up to our mission of promoting better health for individuals and progress in medicine.
  • Growth Toward a World-Class Pharmaceutical Company With Japanese Origin Growth Toward a World-Class Pharmaceutical Company With Japanese Origin Yasuchika Hasegawa, President Takeda Pharmaceutical Company Limited June 14, 2006 2006 2010 Medium-Term Management Plan Takeda Pharmaceutical Company Limited 2 2006 2010 Medium-Term Management Plan2006 2010 Medium-Term Management Plan Preparation stage toward 21st centuryPreparation stage toward 21st century 9595--00 Plan00 Plan 0101--05 Plan05 Plan Growth toward a WorldGrowth toward a World--Class Pharmaceutical CompanyClass Pharmaceutical Company with Japanese Origin, based on Takedawith Japanese Origin, based on Takeda--ismism 0606--10 Plan10 Plan Growth stage toward aGrowth stage toward a ""WorldWorld--ClassClass Pharmaceutical CompanyPharmaceutical Company"" Takeda Pharmaceutical Company Limited 3 Financial Performance: Sales Growth Achieved 15 Years In A Row! Financial Performance: Sales Growth Achieved 15 Years In A Row! 0 250 500 750 1,000 1,250 '90 '91 '92 '
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2009 - 39 - 5. Unconsolidated Financial Statements (1) Unconsolidated Balance Sheets (Millions of yen) Fiscal 2008 (As of March 31, 2009) Fiscal 2009 (As of March 31, 2010) Assets Current assets Cash and deposits 54,426 111,853 Trade notes receivable 4,517 1,939 Trade accounts receivable 177,479 166,403 Marketable securities 201,942 145,973 Merchandise and products 36,415 38,299 Work in process 26,126 30,980 Raw materials and supplies 20,453 22,941 Advance Payments 7 884 Prepaid expenses 2,244 2,104 Deferred tax assets 160,607 194,709 Other current assets 25,428 21,820 Allowance for doubtful receivables (6) (4) Total current assets 709,638 737,901 Fixed assets Tangible fixed assets Buildings 49,257 54,883 Structures 5,117 6,117 Machinery and equipment 18,410 20,045 Vehicles 55 43 Tools, instruments and fixtures 3,153 3,867 Land 20,786 20,950 Lease assets 2,458 2,441 Construction in progress 13,224 64,006 Total tangible
  • 2010 2012 Mid R Pl2010-2012 Mid-Range Plan May 12, 2010 - Transformation for a New Takeda - Yasuchika Hasegawa President & CEO Takeda Pharmaceutical Company Limited Agenda 1 Outcome of 2006-2010 Mid-Range Plan 2 2010-2012 Mid-Range Plan 3 Forecasts for Financial Results 4 Strategic Investments and Returns to Shareholders 2 Operational targets in FY2010 and Results as of End of FY2009 Outcome of 2006-2010 Mid-Range Plan Achievements to date on 2006-2010 Mid-Range Plan Enhancement of R&D pipeline, toward sales of in-house ethical products of 2 trillion yen in FY2015 Not achieved Sales of in-house ethical products: 1.4 trillion yen Not achieved (1.2 trillion yen) Market share*: 2.5% 2.5% (Forecast) *Weighted average of countries where Takeda has its own sales channels R&D expenses: investment up to 20% of the sales of ethical products 22.1% EPS*: CAGR of more than 7% 7.8% (FY2006-FY2009) *Excluding extraordinary income/loss and other extraordinary factors ROE : Maintenance of 14 15% level 14 4% 3 Returns to Sha
  • - 1 - Consolidated Financial Statements for the Fiscal Year Ended March 31, 2009 May 11, 2009 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya (First Section of each), 1-1, Doshomachi 4-chome Fukuoka, Sapporo Chuo-ku, Osaka 540-8645, Japan Code number: 4502 URL: http://www.takeda.co.jp/ Representative: Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81-3-3278-2037 Scheduled date of annual general meeting of shareholders: June 25, 2009 Scheduled date of securities report submission: June 25, 2009 Scheduled date of dividend payment commencement: June 26, 2009 1. Consolidated Results for Fiscal 2008 (April 1, 2008-March 31, 2009) (1) Sales and Income (All amounts are rounded to the nearest million yen) (Percentage figures represent changes from same period o
  • Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) - 16 - (3) Change in accounting principles, procedures and presentation for quarterly consolidated financial statements - Change in accounting standards 1. From the current fiscal year, the Company adopts the "Accounting Standards for Quarterly Financial Statements" (Corporate Accounting Standards No. 12 issued on Mach 14, 2007) and the "Guides for Adopting the Accounting Standards for Quarterly Financial Statements" (Corporate Accounting Standards Adoption Guide No. 14 issued on Mach 14, 2007). The Company also follows the "Rules for Quarterly Consolidated Financial Statements" to prepare its quarterly consolidated financial statements. 2. In and before fiscal 2007, finance lease transactions other than those for which ownership is deemed to be transferred to the lessee had been accounted for by the accounting method used for ordinary lease transactions. From the fir
  • Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) - 21 - From the current fiscal year, the Company adopts the "Accounting Standards for Quarterly Financial Statements" (Corporate Accounting Standards No. 12 issued on March 14, 2007) and the "Guides for Adopting the Accounting Standards for Quarterly Financial Statements" (Corporate Accounting Standards Adoption Guide No. 14 issued on March 14, 2007). The Company also follows the "Rules for Quarterly Consolidated Financial Statements" to prepare its quarterly consolidated financial statements. (4) Notes regarding assumption of a going concern No events to be noted for this purpose (5) Segment Information [Business Segment Information] Six months ended September 30, 2008 (April 1 to September 30, 2008) Millions of yen Segment Account Pharmaceuticals Other Total Eliminations/ Corporate Consolidated Net sales: (1) Sales to outside customers 760,325 46,815 807,140 807,140
  • Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) - 16 - (3) Change in accounting principles, procedures and presentation for quarterly consolidated financial statements - Change in accounting standards 1. From the current fiscal year, the Company adopts the "Accounting Standards for Quarterly Financial Statements" (Corporate Accounting Standards No. 12 issued on Mach 14, 2007) and the "Guides for Adopting the Accounting Standards for Quarterly Financial Statements" (Corporate Accounting Standards Adoption Guide No. 14 issued on Mach 14, 2007). The Company also follows the "Rules for Quarterly Consolidated Financial Statements" to prepare its quarterly consolidated financial statements. 2. In and before fiscal 2007, finance lease transactions other than those for which ownership is deemed to be transferred to the lessee had been accounted for by the accounting method used for ordinary lease transactions. From the fir
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2008 - 46 - 5. Unconsolidated Financial Statements (1) Unconsolidated Balance Sheets (Millions of yen) Previous Year (As of March 31, 2008) Current Year (As of March 31, 2009) Assets Current assets Cash and deposits 108,760 54,426 Trade notes receivable 4,732 4,517 Trade accounts receivable 169,019 177,479 Marketable securities 479,097 201,942 Merchandise 13,569 Products 17,756 Merchandise and products 36,415 Raw materials 18,015 Semi-finished products 20,897 Work in process 1,908 26,126 Supplies 245 Raw materials and supplies 20,453 Advance Payments 6 7 Prepaid expenses 2,455 2,244 Deferred tax assets 117,136 160,607 Other current assets 25,903 25,428 Allowance for doubtful receivables (6) (6) Total current assets 979,493 709,638 Fixed assets Tangible fixed assets Buildings 50,306 49,257 Structures 5,455 5,117 Machinery and equipment 18,833 18,410 Vehicles and other land transportation devices 63 55 Tools, instruments
  • 86 Deloitte Touche Tohmatsu Nakanoshima Central Tower 2-2-7, Nakanoshima, Kita-ku Osaka-shi, Osaka 530-0005 Japan Tel: +81-6-4560-6000 Fax: +81-6-4560-6001 www.deloitte.com/jp To the Board of Directors of Takeda Pharmaceutical Company Limited: We have audited the accompanying consolidated balance sheets of Takeda Pharmaceutical Company Limited and subsidiaries as of March 31, 2007 and 2006, and the related consolidated statements of income, changes in equity, and cash flows for each of the three years in the period ended March 31, 2007, all expressed in Japanese yen. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in Japan. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstate
  • 82 Takeda Annual Report 2006 Deloitte Touche Tohmatsu Nakanoshima Central Tower 2-2-7, Nakanoshima, Kita-ku Osaka-shi, Osaka 530-0005 Japan Tel: +81-6-4560-6000 Fax: +81-6-4560-6001 www.deloitte.com/jp To the Board of Directors of Takeda Pharmaceutical Company Limited: We have audited the accompanying consolidated balance sheets of Takeda Pharmaceutical Company Limited and subsidiaries as of March 31, 2006 and 2005, and the related consolidated statements of income, shareholders' equity, and cash flows for each of the three years in the period ended March 31, 2006, all expressed in Japanese yen. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in Japan. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
  • SUMMARY OF FINANCIAL STATEMENTS (Consolidated) First quarter results for the fiscal year ending March 31, 2007 These financial statements have been prepared for reference only, in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited July 31, 2006 TSE Code: 4502 Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo URL: http://www.takeda.co.jp/ Inquiries: Toyoji Yoshida, Director General Manager President & COO: Yasuchika Hasegawa Corporate Communications Department Telephone: +81 6 6204-2060 / +81 3 3278-2039 1. Information relating to the preparation of quarterly financial statements Adoption of simplified accounting treatments: Adopted Income tax expenses are calculated by multiplying quarterly income before income tax by the estimated tax rate for the fiscal year. Differences in accounting treatments applied compared to previous consolidated fiscal year: None Changes in the scope of consolidation or application of the equity method: Cons
  • (5) Preparation of Consolidated Financial Statements 1) Scope of Consolidation Number of consolidated subsidiaries: 46 companies Names of principal companies and changes in scope of consolidated subsidiaries: Refer to "Consolidated Subsidiaries and Affiliates" in "The Takeda Group". 2) Application of the Equity Method Number of affiliated companies accounted for by the equity method: 21 companies Names of principal companies and changes in scope of affiliated companies accounted for by the equity method: Refer to "Consolidated Subsidiaries and Affiliates" in "The Takeda Group". 3) Items Related to Account Settlement Date of Consolidated Subsidiaries The annual account closing day is December 31 of each year at Tianjin Takeda Pharmaceuticals Co., Ltd (a consolidated subsidiary) and TAP Pharmaceutical Products Inc. (accounted for by equity method. Financial results of these two companies included in the consolidated financial statements of the Company are based on the temporary closing of their accounts on Mar
  • Growth toward a WorldGrowth toward a World--class Pharmaceuticalclass Pharmaceutical Company with Japanese OriginCompany with Japanese Origin YasuchikaYasuchika HasegawaHasegawa President & COOPresident & COO Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited May 11, 2006May 11, 2006 Fiscal 2005 Financial Results andFiscal 2005 Financial Results and Outline ofOutline of ""20062006--2010 Medium2010 Medium--Term Management PlanTerm Management Plan"" AgendaAgenda Fiscal 2005 Financial Results Review of "2001-05 Medium-Term Management Plan" 2006-2010 Medium-Term Management Plan Management tasksManagement tasks 1.1. Enhancement of capability to create new drugsEnhancement of capability to create new drugs through inthrough in--house R&Dhouse R&D activitiesactivities 2. Formulation of2. Formulation of a tria tri--polar marketing functionpolar marketing function 3. Establishment of an efficient3. Establishment of an efficient global management schemeglobal management scheme for corporatefor
  • - 3 - Contents [Summary] 1. Consolidated Results for Fiscal 2006 ・・・・・・・・・・1 2. Dividends ・・・・・・・・・・1 3. Projected Results for Fiscal 2007 ・・・・・・・・・・1 4. Other ・・・・・・・・・・2 (Reference) Summary of Unconsolidated Results ・・・・・・・・・・ 2 [Qualitative Information, Financial Statements and Other Information] 1. Results of Operations ・・・・・・・・・・4 (1) Analysis of Results of Operations ・・・・・・・・・・4 (2) Analysis of Financial Position ・・・・・・・・・・10 (3) Basic Policy for Profit Distribution and Dividends for Fiscal 2006 and 2007 ・・・・・・・・・・11 (4) Risk Factors in Business ・・・・・・・・・・11 2. The Takeda Group ・・・・・・・・・・13 3. Management Policy ・・・・・・・・・・16 (1) Basic Management Policy ・・・・・・・・・・16 (2) Litigation etc. ・・・・・・・・・・17 4. Consolidated Financial Statements ・・・・・・・・・・18 (1) Consolidated Balance Sheets ・・・・・・・・・・18 (2) Consolidated Statements of Income ・・・・・・・・・
  • - Methods of hedge accounting The Takeda Group uses mainly deferred hedging. However, under certain conditions, forward exchange contracts and interest rate swaps are accounted for as if each hedging instrument and hedged item were one combined financial instrument. - Hedging instruments, hedging targets and hedging policies The Takeda Group uses interest swaps and option transactions to hedge the portion of cash flow related to future asset management income, which is linked to short-term variable interest rates. In addition, the Takeda Group uses forward foreign exchange contracts and currency options to hedge those foreign currency-denominated transactions that can be individually recognized and are financially material. These hedge transactions are conducted in accordance with established regulations regarding scope of usage and standards for selection of counterparty financial institutions. - Method of assessing effectiveness of hedges Preliminary testing is conducted using comparative analysis or stati
  • 1 SUMMARY OF FINANCIAL STATEMENTS (Consolidated) First three quarters results for the fiscal year ending March 31, 2006 These financial statements have been prepared for reference only, in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited January 31, 2006 TSE Code: 4502 Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo URL: http://www.takeda.co.jp/ Inquiries: Toyoji Yoshida, Director General Manager President & COO: Yasuchika Hasegawa Corporate Communications Department Telephone: +81 6 6204-2060 / +81 3 3278-2039 1.Information relating to the preparation of quarterly financial statements 1) Adoption of simplified accounting treatments: Income tax expenses are calculated by multiplying quarterly income before income tax by the estimated tax rate for the fiscal year. 2) Differences in accounting treatments applied compared to previous consolidated fiscal year: Method of allocating operating expenses to business segments has been chang
  • Growth toward a WorldGrowth toward a World--class Pharmaceuticalclass Pharmaceutical Company with Japanese OriginCompany with Japanese Origin YasuchikaYasuchika HasegawaHasegawa President & COOPresident & COO Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited May 11, 2006May 11, 2006 Fiscal 2005 Financial Results andFiscal 2005 Financial Results and Outline ofOutline of ""20062006--2010 Medium2010 Medium--Term Management PlanTerm Management Plan"" AgendaAgenda Fiscal 2005 Financial Results Review of "2001-05 Medium-Term Management Plan" 2006-2010 Medium-Term Management Plan Management tasksManagement tasks 1.1. Enhancement of capability to create new drugsEnhancement of capability to create new drugs through inthrough in--house R&Dhouse R&D activitiesactivities 2. Formulation of2. Formulation of a tria tri--polar marketing functionpolar marketing function 3. Establishment of an efficient3. Establishment of an efficient global management schemeglobal management scheme for corporatefor

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next

Page Top